Immunotherapy for malignant gliomas

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Cancer immunotherapy aims to harness the innate ability of the immune system to recognize and destroy malignant cells. Immunotherapy for malignant gliomas is an emerging field that promises the possibility of highly specific and less toxic treatment compared to conventional chemotherapy. In addition, immunotherapy has the added benefit of sustained efficacy once immunologic memory is induced. Although there are numerous therapeutic agents that boost general immune function and facilitate improved antitumor immunity, to date, immunotherapy for gliomas has focused primarily on active vaccination against tumor-specific antigens. The results of numerous early phase clinical trials demonstrate promising results for vaccine therapy, but no therapy has yet proven to improve survival in a randomized, controlled trial. The major barrier to immunotherapy in malignant gliomas is tumor-induced immunosuppression. The mechanisms of immunosuppression are only now being elucidated, but clearly involve a combination of factors including regulatory T cells, tumor-associated PD-L1 expression, and CTLA-4 signaling. Immunomodulatory agents have been developed to combat these immunosuppressive factors and have demonstrated efficacy in other cancers. The future of glioma immunotherapy likely lies in a combination of active vaccination and immune checkpoint inhibition.

Original languageEnglish (US)
Pages (from-to)143-158
Number of pages16
JournalCancer Treatment and Research
Volume163
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Glioma
Immunotherapy
Immunosuppression
Neoplasms
Vaccination
Immunologic Memory
Active Immunotherapy
Poisons
Neoplasm Antigens
Regulatory T-Lymphocytes
Immunosuppressive Agents
Immune System
Immunity
Therapeutics
Randomized Controlled Trials
Clinical Trials
Drug Therapy

Keywords

  • CTLA-4
  • Glioblastoma
  • Glioma
  • Immunotherapy
  • PD-1
  • PD-L1
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Immunotherapy for malignant gliomas. / Bloch, Orin.

In: Cancer Treatment and Research, Vol. 163, 01.01.2015, p. 143-158.

Research output: Contribution to journalArticle

@article{0a7d33ec9eb24bbfaf9ecc625203b22e,
title = "Immunotherapy for malignant gliomas",
abstract = "Cancer immunotherapy aims to harness the innate ability of the immune system to recognize and destroy malignant cells. Immunotherapy for malignant gliomas is an emerging field that promises the possibility of highly specific and less toxic treatment compared to conventional chemotherapy. In addition, immunotherapy has the added benefit of sustained efficacy once immunologic memory is induced. Although there are numerous therapeutic agents that boost general immune function and facilitate improved antitumor immunity, to date, immunotherapy for gliomas has focused primarily on active vaccination against tumor-specific antigens. The results of numerous early phase clinical trials demonstrate promising results for vaccine therapy, but no therapy has yet proven to improve survival in a randomized, controlled trial. The major barrier to immunotherapy in malignant gliomas is tumor-induced immunosuppression. The mechanisms of immunosuppression are only now being elucidated, but clearly involve a combination of factors including regulatory T cells, tumor-associated PD-L1 expression, and CTLA-4 signaling. Immunomodulatory agents have been developed to combat these immunosuppressive factors and have demonstrated efficacy in other cancers. The future of glioma immunotherapy likely lies in a combination of active vaccination and immune checkpoint inhibition.",
keywords = "CTLA-4, Glioblastoma, Glioma, Immunotherapy, PD-1, PD-L1, Vaccine",
author = "Orin Bloch",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-12048-5_9",
language = "English (US)",
volume = "163",
pages = "143--158",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Immunotherapy for malignant gliomas

AU - Bloch, Orin

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Cancer immunotherapy aims to harness the innate ability of the immune system to recognize and destroy malignant cells. Immunotherapy for malignant gliomas is an emerging field that promises the possibility of highly specific and less toxic treatment compared to conventional chemotherapy. In addition, immunotherapy has the added benefit of sustained efficacy once immunologic memory is induced. Although there are numerous therapeutic agents that boost general immune function and facilitate improved antitumor immunity, to date, immunotherapy for gliomas has focused primarily on active vaccination against tumor-specific antigens. The results of numerous early phase clinical trials demonstrate promising results for vaccine therapy, but no therapy has yet proven to improve survival in a randomized, controlled trial. The major barrier to immunotherapy in malignant gliomas is tumor-induced immunosuppression. The mechanisms of immunosuppression are only now being elucidated, but clearly involve a combination of factors including regulatory T cells, tumor-associated PD-L1 expression, and CTLA-4 signaling. Immunomodulatory agents have been developed to combat these immunosuppressive factors and have demonstrated efficacy in other cancers. The future of glioma immunotherapy likely lies in a combination of active vaccination and immune checkpoint inhibition.

AB - Cancer immunotherapy aims to harness the innate ability of the immune system to recognize and destroy malignant cells. Immunotherapy for malignant gliomas is an emerging field that promises the possibility of highly specific and less toxic treatment compared to conventional chemotherapy. In addition, immunotherapy has the added benefit of sustained efficacy once immunologic memory is induced. Although there are numerous therapeutic agents that boost general immune function and facilitate improved antitumor immunity, to date, immunotherapy for gliomas has focused primarily on active vaccination against tumor-specific antigens. The results of numerous early phase clinical trials demonstrate promising results for vaccine therapy, but no therapy has yet proven to improve survival in a randomized, controlled trial. The major barrier to immunotherapy in malignant gliomas is tumor-induced immunosuppression. The mechanisms of immunosuppression are only now being elucidated, but clearly involve a combination of factors including regulatory T cells, tumor-associated PD-L1 expression, and CTLA-4 signaling. Immunomodulatory agents have been developed to combat these immunosuppressive factors and have demonstrated efficacy in other cancers. The future of glioma immunotherapy likely lies in a combination of active vaccination and immune checkpoint inhibition.

KW - CTLA-4

KW - Glioblastoma

KW - Glioma

KW - Immunotherapy

KW - PD-1

KW - PD-L1

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84916604843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916604843&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-12048-5_9

DO - 10.1007/978-3-319-12048-5_9

M3 - Article

C2 - 25468230

AN - SCOPUS:84916604843

VL - 163

SP - 143

EP - 158

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -